Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
18.1
Price to sales ratio
5.23
Dividends per share
3.16
Dividend yield %
2.57

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
48
NVS
Novartis AG
143.77 USD+0.45%+2.01%+1.50%+10.93%274.33 B USD
65
AMGN
Amgen Inc. - Common Stock
414.87 USD+1.82%+3.97%+8.34%+42.29%224.29 B USD
95
PFE
Pfizer, Inc. Common Stock
28.27 USD+1.58%+2.24%+0.68%+14.04%161.13 B USD
128
BMY
Bristol-Myers Squibb Company Common Stock
59.11 USD-0.76%-1.17%-9.09%+35.14%120.74 B USD

Frequently asked questions about Gilead Sciences Inc

What is the Gilead Sciences Inc stock price today?

The current price of Gilead Sciences Inc (GILD) is 151.17. Over the past 24 hours, the stock has changed by +2.77%. Follow the GILD chart for real-time price dynamics.

What is the stock ticker of Gilead Sciences Inc?

Gilead Sciences Inc trades under the ticker GILD. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Gilead Sciences Inc stock going up?

GILD has changed by +5.56% over the last week, +3.85% over the last month, and +30.21% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Gilead Sciences Inc?

Gilead Sciences Inc currently has a market capitalization of 187.44 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does Gilead Sciences Inc release financial reports?

Yes. You can track Gilead Sciences Inc financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What were Gilead Sciences Inc earnings last quarter?

Last quarter, Gilead Sciences Inc reported earnings of -8.45 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Gilead Sciences Inc revenue for the last quarter?

Gilead Sciences Inc reported quarterly revenue of 7.8 B. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Gilead Sciences Inc net income for the last quarter?

Gilead Sciences Inc reported net income of -10.5 B for the last quarter. The previous quarter showed 2.02 B, which means net income changed by -619.35%.

Does Gilead Sciences Inc pay dividends?

Gilead Sciences Inc paid a dividend per share of 0.82. The current dividend yield is 4.42%. Dividend data can help income-focused investors evaluate the stock.

Is Gilead Sciences Inc a good dividend stock?

Gilead Sciences Inc currently has a dividend yield of 4.42%. Previously, the dividend yield was 3.99%, compared with 2.57% a year earlier. When evaluating dividend stocks, investors should also consider earnings, cash flow, and the sustainability of future dividend payments.

How many employees does Gilead Sciences Inc have?

As of the latest available data, Gilead Sciences Inc has 17 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Gilead Sciences Inc EBITDA?

Gilead Sciences Inc EBITDA is -9.7 B, and its EBITDA margin is -124.26%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Gilead Sciences Inc stock?

You can buy Gilead Sciences Inc (GILD) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Gilead Sciences Inc stock?

Investing in Gilead Sciences Inc requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the GILD chart and related analysis on metatrader.com as part of your research.

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.

News